Revenues

3 Months Ended

Mar. 31, 2021

Revenues

Revenues

3.     Revenues

As discussed in Note 2, revenues are recognized under guidance within ASC 606. The following table presents our disaggregated revenue for the periods presented (in thousands):

	Three Months Ended
	March 31,
	2021		2020
JAKAFI revenues, net	$	465,710	$	459,479
ICLUSIG revenues, net		25,645		27,248
PEMAZYRE revenues, net		13,456		—
Total product revenues, net		504,811		486,727
JAKAVI product royalty revenues		65,602		56,333
OLUMIANT product royalty revenues		32,258		25,447
TABRECTA product royalty revenues		2,047		—
Total product royalty revenues		99,907		81,780
Total revenues	$	604,718	$	568,507

For further information on our revenue-generating contracts, refer to Note 9.